Drug General Information (ID: DDIUZ1AHD4)
Drug Name			Pegvisomant		Drug Info		Linagliptin		Drug Info
Drug Type		Hormones				Small molecule
Therapeutic Class		Anabolic Agents				Dpp4 Inhibitors/Antidiabetic Agents

Mechanism of Pegvisomant-Linagliptin Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Pegvisomant				Linagliptin
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Pegvisomant and Linagliptin

Recommended Action
Management		Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.

References
1	Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
2	Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72. [PMID: 6781341]
3	Product Information. Somavert (pegvisomant). Pharmacia and Upjohn, Kalamazoo, MI.